超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

百奧邁科 Biomics
百奧邁科(Biomics)生物技術有限公司，是由國家“千人計劃”專家朱遠源博士率領的海歸科研、管理團隊于2006年在南通經濟技術開發區創立，注冊資本1212萬美元，總投資2500萬美元，致力于第三代制藥——小核酸藥物研發與產業化。

　　百奧邁科由海歸高層次人才領軍研發、管理，目前擁有海歸專家十余名；在百余名員工中，專業人員占60%以上，博士、碩士二十余名。公司占地100畝，目前已建有一期一萬平方米的小核酸藥物研發生產基地，設有一流的研發生產設備。

　　百奧邁科發展至今，建立了小核酸文庫構建、靶點高通量篩選、結構修飾、規模化化學合成、藥物傳輸系統等技術于一體的完整藥物開發技術鏈。正在研發的多個抗腫瘤、抗病毒小核酸藥物取得突破性進展。獲得國內外發明專利40余項。2009年，百奧邁科投資成立了控股子公司“江蘇吉康生物技術有限公司”，推出世界首例小核酸美白祛斑產品，填補了國內外空白，搶占了產業國際制高點。目前已經形成以科研試劑和技術外包服務為短線產品、以小核酸美白祛斑系列產品為中線產品及以小核酸藥物研發、生產和銷售為長線產品的完整商務模式。

　　百奧邁科先后被評為國家博士后科研工作站、國家級高新技術企業、江蘇省工程技術研究中心等。2011年，百奧邁科成為“十二五”規劃全國唯一的小核酸重大新藥創制基地。另外，還承擔了多項國家、省、市級科技項目。

　　基于前沿的科研水平，百奧邁科建立了與國際知名藥企Benitec公司、Zetiq公司的科研合作。憑借良好的發展前景，百奧邁科正在凝聚更多力量，創新開拓，創業進取，努力將企業打造成世界一流的核酸制藥集團，為中國第三代新藥創制闖出一片新天地。

 Biomics Biotechnologies co. Ltd. is a pharmaceutical company in developing and commercializing RNAi based innovative products for disease treatments. The company was founded by Dr. York Zhu in 2006, registered with $ 12.12 M.

The company is managed by a professional team which is consisted with several oversea returnees. Over 60% of employees are with college degrees or above, including over 20 PhDs and Masters.

Biomics owns 16.6 acre land including 10000 m2 well-equipped R&D facility and possesses a comprehensive RNAi drug developing platforms comprised of Entire siRNA Targets Library, High-throughput Screening, Large-scale Synthesis, siRNA Delivery System and in-vivo Evaluation System. In addition, the company owns over 40 national and international patents.

Meanwhile, company possesses a pipeline with several ongoing programs for the treatments of Age-related Macular Degeneration (AMD), Hepatitis B, Bladder Cancer and other serious diseases. In 2009, first RNAi based product was launched by Genecon Biotech, a subsidiary of Biomics, for use of depigmentation. AMD candidate developed by Biomics scientists was successfully launched to pre-clinical stage which. It is not only an excellent validation of the company’s sophisticated technologies, but also a strong statement of the researchers' capabilities.

With the boost of Biomics in the last five years, in 2011, the company was selected as a national RNAi base. Additionally, Biomics has collaborative and partnership agreements with leading institutes worldwide, including Peking University, Benitec Biopharma (Australia) and Zetiq Technologies (Israel).